Amycretin Weight Loss Pill: How It Works and When It's Coming
Novo Nordisk's promising new weight loss pill Amycretin targets two hunger hormones and shows impressive early results, but it won't be available until 2030.
Written and medically reviewed by:
Key Takeaways
Amycretin is Novo Nordisk's experimental weight loss pill that targets two hunger hormones and shows impressive early results. It won't be available until around 2030, but current proven options like Wegovy and Mounjaro are available now.
Amycretin Weight Loss Pill: How It Works and When It's Coming
Amycretin is an experimental weight loss pill from Novo Nordisk that's showing remarkable promise in early trials. Unlike current UK-approved options like orlistat, this new medication targets two hunger hormones simultaneously - potentially making it more effective than existing treatments like Wegovy.
While Amycretin won't be available until around 2030, understanding how it works helps explain why researchers are excited about this potential game-changer in weight management.
What Makes Amycretin Different#
Amycretin is what's called a dual hormone agonist - it mimics both GLP-1 and amylin, two naturally occurring hormones that control hunger and blood sugar. This dual approach sets it apart from current weight loss medications.
Most existing treatments work on just one pathway. Wegovy and Saxenda mimic GLP-1 alone, while Mounjaro targets GLP-1 plus GIP. Orlistat works differently altogether by blocking fat absorption in your gut.
By targeting both GLP-1 and amylin together, Amycretin could potentially offer better appetite control with fewer digestive side effects - though we need more research to confirm this.
How Amycretin Works for Weight Loss#
The two hormones Amycretin mimics work together to reduce appetite:
GLP-1's effects:
- Slows digestion, keeping you full longer
- Signals your brain to reduce cravings
- Helps regulate blood sugar after meals
- Reduces the urge to snack between meals
Amylin's effects:
- Creates feelings of satiety during meals
- Slows stomach emptying
- Helps stabilise blood sugar
- May work more through the brain than the gut
This combination means you naturally eat less without the constant hunger that makes other diets difficult to stick to.
Early Results Look Promising#
The clinical trial results for Amycretin have been impressive, though we're still in early stages:
- Oral version: People lost 13.1% of their body weight in just 12 weeks on the highest dose
- Injectable version: 22% weight loss after 36 weeks on the 20mg weekly dose
- Comparison: Wegovy typically produces 14.9% weight loss after 68 weeks
These results suggest Amycretin could work faster and potentially better than current options. However, we don't yet know if this rate of loss continues long-term or plateaus like other medications.
Side Effects and Safety Profile#
Based on early trials, Amycretin's side effects appear similar to other GLP-1 medications:
Common side effects include:
- Nausea (usually mild and temporary)
- Vomiting
- Diarrhoea
- Constipation
- Stomach discomfort
One potential advantage is that because amylin may work more through brain signals than gut effects, Amycretin might cause fewer digestive problems than current injections. However, this is still being studied.
Like all weight loss medications, Amycretin will likely have contraindications and won't be suitable for everyone. The full safety profile will become clearer as trials progress.
Comparing Amycretin to Current UK Options#
How does Amycretin stack up against what's available now?
Weight loss effectiveness:
- Orlistat: About 40% of people lose 10% of body weight after one year
- Saxenda: Average 7.4% weight loss after 52 weeks
- Wegovy: 14.9% after 68 weeks, 20.7% with higher dose after 72 weeks
- Mounjaro: 25.3% after 88 weeks (highest currently available)
- Amycretin: 22% after just 36 weeks (early data)
Convenience factor: Amycretin's biggest advantage may be that it's a daily pill rather than weekly injections. Many people prefer tablets to self-administered injections, which could improve treatment adherence.
When Will Amycretin Be Available?#
Novo Nordisk has stated they're confident Amycretin will launch before 2030, but several hurdles remain:
- Phase 2 and 3 trials: These larger, longer studies will determine effectiveness and safety
- Regulatory approval: Submissions to FDA, EMA, and MHRA
- Manufacturing scale-up: Producing enough medication for global demand
- Pricing negotiations: Discussions with health services like the NHS
Given current timelines, we're likely looking at 2028-2030 for UK availability, assuming trials continue to show positive results.
What This Means for UK Patients#
For now, Amycretin remains experimental. If you're considering weight loss medication today, proven options are available through Totiva and other GPhC-registered pharmacies.
Current UK-approved treatments include:
- Orlistat (Alli, Orlos): The only licensed oral weight loss medication
- Wegovy: Weekly GLP-1 injection with strong evidence
- Saxenda: Daily GLP-1 injection option
- Mounjaro: Dual hormone injection showing excellent results
While we wait for Amycretin, these established treatments can help you start your weight loss journey now. The key is finding the right medication and support system for your individual needs.
If you're interested in exploring current weight loss medication options, speak with a healthcare provider who can assess your eligibility and help you choose the most suitable treatment for your situation.
Medical Information: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any treatment.
